EMA Authorised: Pemetrexed Fresenius Kabi (pemetrexed) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

The EMA authorised Pemetrexed Fresenius Kabi (pemetrexed) for use in non-small cell lung cancer and malignant mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Mesothelioma. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 19/12/2024